Search for: Twitter YouTube LinkedIn Email Personalis Publishes New Data Demonstrating Performance and Utility of SHERPA for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development Personalis Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients The Personalis Mission To transform the development of next-generation cancer therapies by providing more comprehensive molecular data about each patient’s tumor. Elucidating Complex Biology in the Immuno-Oncology Era Effectively predicting response to emerging precision oncology therapies — and developing new ones — requires a more comprehensive approach to tumor immunogenomics. By providing the most extensive molecular view of a patient’s tumor and characterizing its interplay with the immune system, the Personalis NeXT Platform™ enables the identification of next-generation composite biomarkers, with the ultimate goal of bringing the revolutionary potential of precision medicine to more cancer patients. Through partnerships with some of the world’s largest and most innovative biopharmaceutical companies, Personalis aids in the development of safer, more effective precision cancer therapies, immunotherapies, and personalized medicines. ImmunoID NeXT™ The Universal Cancer Immunogenomics Platform ImmunoID NeXT is the first platform to enable the comprehensive analysis of both a tumor and its microenvironment from a single sample. Providing genomic information for all ~20,000 genes, ImmunoID NeXT consolidates multiple oncology biomarker assays into one – maximizing the biological insights gained from a single sample. When specimens are limited, researchers must make difficult decisions regarding which biomarkers to analyze. With ImmunoID NeXT, this problem is a thing of the past. A Single Platform. A Single Sample. Multiple Biomarkers. Learn More NeXT Liquid Biopsy™ Complementing Tumor Tissue Profiling with Plasma-based Global Resolution NeXT Liquid Biopsy, a first-of-its-kind, high-performance, whole-exome liquid biopsy assay, is designed to complement ImmunoID NeXT, providing a comprehensive view of the tumor’s mutational landscape. For the first time, researchers have the ability to track and interrogate key areas of tumor biology that may lead to therapy resistance and cancer progression from an exome-wide perspective with confidence. It’s time to think about more. High-performance whole-exome sequencing from plasma. Learn More Predictive & Prognostic Biomarker Discovery ImmunoID NeXT provides a multidimensional view of the tumor and the TME, empowering our partners to extract the most information from the least amount of sample. Ready to streamline your precision oncology translational and clinical research programs? Contact Us Join Us! Immuno UK 2021, London and Online | October 13-14 Japan Society of Clinical Oncology (JSCO) 2021, Yokohama and Online | October 21-23 Neoantigen Based Therapies Summit US 2021, Online | October 26-28 Biomarkers UK > Lung Cancer Summit 2021, Online | November 8-9 SITC Annual Meeting, Washington DC and Online | November 10-14 Learn More Personalis Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients COVID-19 UPDATE ABOUT Company Leadership Laboratory Careers Contact PRODUCTS Immuno-/Precision Oncology Oncology Clinical Diagnostics Pharma Research Solutions APPLICATIONS Biomarker Discovery Personalized Therapeutics Population Genomics TECHNOLOGY RESOURCES What’s New Conferences Library Publications Blog Contact INVESTORS © 2021 Personalis Inc. All rights reserved. info@personalis.com1 855-GENOME4 (436-6634)1 650-752-1300Privacy Policy We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. Do not sell my personal information. Cookie Settings Accept